{"entity":{"id":"nct06907043","kind":"trial","name":"A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.","aka":[],"tldr":"This study tests a PARP inhibitor; the registry reports that it is recruiting.","summary":"The registry lists NCT06907043 as recruiting, last updated 2025-08-19. Enrolment is 130 planned participants, an estimate. Interventions: EIK1004-001 (IMP1707-001). Primary measures include Number of Participants who experience a Dose-Limiting Toxicity (DLT); Number of participants with adverse events, treatment emergent adverse events or serious adverse events. No results are posted in the registry; this does not exclude separate publications.","status":"recruiting","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT06907043","url":"https://clinicaltrials.gov/study/NCT06907043"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":["parp"],"drugs":["eik1004"],"companies":["eikon-therapeutics","impact-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06907043","phase":"1/2","setting":"A Phase 1/2, Open-label, Multicenter, Dose-escalation, and Dose-Optimization Study to Evaluate the Safety, Tolerability, and Activity of EIK1004 (IMP1707) as Monotherapy in Participants With Advanced Solid Tumors","sponsor":"Eikon Therapeutics","participation":[{"nct":"NCT06907043","source":"https://clinicaltrials.gov/study/NCT06907043","fetchedAt":"2026-10-07T16:55:17.578Z","studySha256":"9b70562402d8cfbfb75edfad1e72996438442116bd78659df02ed114ee289af1","overallStatus":"RECRUITING","lastUpdatePosted":"2025-08-19","leadSponsor":"Eikon Therapeutics","collaboratorCount":1,"minimumAge":"18 Years","maximumAge":"89 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":130,"enrolmentType":"ESTIMATED","siteCount":10,"recruitingSiteCount":10,"countries":["Australia","China","United States"]}],"started":"2025-04-30","startedType":"actual","enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06907043/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"target":[{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"drug":[{"id":"eik1004","kind":"drug","name":"EIK1004","route":"/drugs/eik1004/"}],"company":[{"id":"eikon-therapeutics","kind":"company","name":"Eikon Therapeutics","route":"/companies/eikon-therapeutics/"},{"id":"impact-therapeutics","kind":"company","name":"IMPACT Therapeutics","route":"/companies/impact-therapeutics/"}]}}